Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1

Interventions

Cyclophosphamide 207fludarabine phosphate 182Azacitidine 153fludarabine 141Busulfan 139Tacrolimus 118Mycophenolic Acid 111Cytarabine 110Whole-Body Irradiation 105Peripheral Blood Stem Cell Transplantation 97Antilymphocyte Serum 95Melphalan 89Filgrastim 86Cyclosporine 81Methotrexate 78Decitabine 78venetoclax 63Granulocyte Colony-Stimulating Factor 56Radiotherapy 49Stem Cell Transplantation 48Thiotepa 46Cord Blood Stem Cell Transplantation 43thymoglobulin 41Clofarabine 41Etoposide 35Specimen Handling 34Methylprednisolone 34Sirolimus 33Biopsy 27Injections 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myelodysplastic Syndromes × seclidemstat × Other hematologic neoplasm × Clear all
NCT04734990 2026-04-02

Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
24 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡